News Sentiment

RLMD sentiment intelligence

Relmada Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.41 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.1% over one week, -3.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

RELMADA THERAPEUTICS INC (RLMD) Stock Chart

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 2.1% Price confirming higher
Trend fit Trend active -3.6% over four weeks
Fair value 106.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 34
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 7
TradingKey 5
Stock Titan 4
GlobeNewswire 4
Moomoo 3
MT Newswires 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 16
Analyst action 12
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
MarketBeat Direct company coverage

Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026

Relmada Therapeutics (RLMD) saw a significant increase in short interest, with 10.65 million shares sold short as of June 30, 2026, marking a 75.70% rise from the previous report. The short interest ratio stands at 3.1 days to cover, and 11.87% of the public float is sold short.

Tone
Negative 42/100
Event
Market update
Published
10 Jul 2026 09:40
Source
MarketBeat
Finviz Direct company coverage

RLMD - Relmada Therapeutics Inc Options

This article provides a detailed financial overview of Relmada Therapeutics Inc (RLMD) options, including its last closing price, market capitalization, various financial ratios, and stock performance metrics. It lists key data points such as EPS, sales growth, insider/institutio

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 10:10
Source
Finviz
TradingView Direct company coverage

Price to book forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD

The article displays the "Price to book forward" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It provides the financial data for the company under this specific financial analysis category. The content is presented with a focus on financial information related to the sto

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 06:40
Source
TradingView
Market source Direct company coverage

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics, a clinical-stage biotechnology company, announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective after market close on June 26, 2026. This inclusion reflects the company's progress, including robust 12-month data for its NDV-01 candi

Tone
Positive 81/100
Event
Market update
Published
30 Jun 2026 05:10
Source
Market source
marketscreener.com Direct company coverage

Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark

Relmada Therapeutics, Inc. (NasdaqCM: RLMD) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. This follows several other recent inclusions in various Russell indices, including the Russell 2000, Russell 3000, and Russel

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 19:39
Source
marketscreener.com
Stock Titan Direct company coverage

Relmada lands in Russell 2000 and Russell 3000 after reconstitution

Relmada Therapeutics (Nasdaq: RLMD) announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026. This addition, part of the Russell Indexes reconstitution, is a significant accomplishment reflecting the company's pr

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 11:12
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD

The article focuses on the "Price to earnings forward" metric for Relmada Therapeutics, Inc. (NASDAQ: RLMD). It appears to be a financial data snippet from TradingView, indicating a specific financial valuation measure for the company. The content itself provides the context of w

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 10:12
Source
TradingView
www.marketscreener.com Direct company coverage

Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Index

Relmada Therapeutics, Inc. (NasdaqCM:RLMD), a clinical-stage biotechnology company specializing in CNS and metabolic disorders, has been added to the Russell 2500 Index. This inclusion follows several other recent additions to various Russell indexes, including the Russell Small

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 05:10
Source
www.marketscreener.com
Simply Wall Street Direct company coverage

RLMD: Next-Generation Bladder Cancer Therapy Platform Will Drive Future Upside Potential

The fair value estimate for Relmada Therapeutics (RLMD) has increased to $12.67, driven by a new analyst target and the perceived differentiation of its NDV-01 platform for bladder cancer therapy. The company has also increased its authorized common stock and was added to the S&P

Tone
Positive 72/100
Event
Analyst action
Published
27 Jun 2026 04:09
Source
Simply Wall Street
Timothy Sykes Direct company coverage

RLMD Jumps As HC Wainwright Launches Buy Coverage

Relmada Therapeutics Inc. (RLMD) saw its stock jump by 3.72% after H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, driven by optimism for its NDV-01 clinical trial. Despite current negative earnings and heavy R&D burn, the company maintains a strong b

Tone
Positive 72/100
Event
Analyst action
Published
26 Jun 2026 20:38
Source
Timothy Sykes
TradingView Direct company coverage

Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD)

This article provides an overview of Relmada Therapeutics, Inc. (NASDAQ: RLMD) stock, including its current price, market capitalization, and analyst forecasts. It details historical performance, future earnings estimates, and answers frequently asked questions regarding its fina

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

RLMD Forecast — Price Target — Prediction for 2027

Relmada Therapeutics, Inc. (RLMD) has a one-year price target of $12.67 based on 6 analyst forecasts. Analysts predict a maximum price of $19.00 and a minimum of $9.00 for RLMD. The company's stock has seen a significant increase of 1190% over the last year, despite recent weekly

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 05:39
Source
TradingView
Stock Titan Direct company coverage

Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported shared voting and dispositive power over 4,567,952 shares of Relmada Therapeutics (NASDAQ: RLMD), representing 4.4% of the common stock. This Schedule 13G filing indicates that the r

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 21:10
Source
Stock Titan
Investing.com Direct company coverage

Relmada Therapeutics stock maintained at Buy by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $12.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD), highlighting the company's strong financial position and promising clinical pipeline for its NDV-01 program. Despite a recent net loss that slightly missed analyst fo

Tone
Positive 74/100
Event
Analyst action
Published
23 Jun 2026 12:12
Source
Investing.com
StreetInsider Direct company coverage

H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)

H.C. Wainwright analyst Andres Maldonado has reiterated a Buy rating on Relmada Therapeutics Inc (RLMD) with a $12.00 price target. The article, published on June 23, 2026, is a premium content piece and requires a subscription to StreetInsider.com for full access.

Tone
Positive 77/100
Event
Analyst action
Published
23 Jun 2026 11:12
Source
StreetInsider
Investing.com Nigeria Direct company coverage

Form 13G Relmada Therapeutics For: 22 June By Investing.com

This article reports on a Form 13G filing for Relmada Therapeutics, dated June 22. It mentions the stock symbol RLMD and includes minor fluctuations in various global indices and commodities. The primary content of the article is the announcement of the Form 13G filing itself, wi

Tone
Negative 42/100
Event
Market update
Published
23 Jun 2026 01:40
Source
Investing.com Nigeria
marketscreener.com Direct company coverage

Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index

Relmada Therapeutics, Inc. (NasdaqCM:RLMD) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biotechnology firm focused on developing therapies for central nervous system (CNS) and metabolic disorders, with its lead product candidate

Tone
Positive 76/100
Event
Market update
Published
22 Jun 2026 13:09
Source
marketscreener.com
TradingKey Direct company coverage

Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Relmada Therapeutics Inc (RLMD), noting its current risk score of 1.94, ranking 255 out of 389 in the Biotechnology & Medical Research industry. The company's beta is 0.40, indicating lower volatility relative to the S&P 500. The assess

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 08:39
Source
TradingKey
GuruFocus Direct company coverage

RLMD Initiates Coverage On by HC Wainwright & Co. -- Rating Set to Buy

HC Wainwright & Co. initiated coverage on Relmada Therapeutics (RLMD) with a 'Buy' rating and a $12.00 target price. Despite a low GF Score™ of 30/100 due to profitability and growth concerns, the company exhibits strong financial health. Analysts are confident in RLMD's potentia

Tone
Positive 68/100
Event
Analyst action
Published
18 Jun 2026 11:39
Source
GuruFocus
Investing.com Direct company coverage

H.C. Wainwright initiates Relmada stock coverage with buy rating

H.C. Wainwright has initiated coverage on Relmada Therapeutics Inc (NASDAQ:RLMD) with a Buy rating and a $12 price target, citing its promising NDV-01 for non-muscle invasive bladder cancer. The stock has seen an impressive 843% one-year return, despite the company currently bein

Tone
Positive 71/100
Event
Analyst action
Published
18 Jun 2026 11:08
Source
Investing.com